UTHRUnited Therapeutics Corporation

$549.48+32% 1Y

Is it growing?

Mixed

Neither accelerating nor breaking down: nothing decisive, though operating margin narrowing (−2.6 points).

1 to watch, 2 neutral
Revenue trend+2% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings.

Earnings trend+9% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.

Margin direction−2.6 points operating

Trailing-twelve-month operating margin, 44.4% now against 47.1% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearsbetter than 78% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is UTHR growing?

United Therapeutics Corporation has grown revenue 14% a year over three years and 16% a year over five, with earnings per share compounding at 17%.

+14%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +13% · steady growth, ahead of inflation · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate
+16%

Revenue growth, 5-year rate · +14% over three · growth has slowed since the five-year average

Earnings per share, 3-year rate
+17%

Earnings per share, 3-year rate · revenue +14% · earnings outgrew revenue: margins or the share count worked for shareholders

Years of annual history on file
18

Years of annual history on file · FY2008 to FY2025, as filed

Details›
Revenue FY2021
$1.69B
Revenue FY2022
$1.94B
Revenue FY2023
$2.33B
Revenue FY2024
$2.88B
Revenue FY2025
$3.18B

Annual income statements as filed with the SEC.